1 July 2015 in European Journal of Pharmaceutical Sciences
1 September 2019 in International Journal of Nanomedicine
Background: Endogenously expressed microRNAs (miRNAs) have attracted attention as important regulators in post-transcriptionally controlling gene expression of various physiological processes. As miRNA dysregulation is often associated with various disease patterns, such as obesity, miRNA-27a might therefore be a promising candidate for miRNA mimic replacement therapy by inhibiting adipogenic marker genes. However, application of naked nucleic acids faces some limitations concerning poor enzymatic stability, bio-membrane permeation and cellular uptake. To overcome these obstacles, the development of appropriate drug delivery systems (DDS) for miRNAs is of paramount importance. Methods: In this work, a triple combination of atomic force microscopy (AFM), brightfield (BF) and fluorescence microscopy was used to trace the cellular adhesion of N-TER peptide-nucleic acid complexes followed by time-dependent uptake studies using confocal laser scanning microscopy (cLSM). To reveal the biological effect of miRNA-27a on adipocyte development after transfection treatment, Oil-Red-O (ORO)- staining was performed to estimate the degree of in lipid droplets accumulated ORO in mature adipocytes by using light microscopy images as well as absorbance measurements. Results: The present findings demonstrated that amphipathic N-TER peptides represent a suitable DDS for miRNAs by promoting non-covalent complexation through electrostatic interactions between both components as well as cellular adhesion of the N-TER peptide – nucleic acid complexes followed by uptake across cell membranes and intracellular release of miRNAs. The anti-adipogenic effect of miRNA-27a in 3T3-L1 cells could be detected in mature adipocytes by reduced lipid droplet formation. Conclusion: The present DDS assembled from amphipathic N-TER peptides and miRNAs is capable of inducing the anti-adipogenic effect of miRNA-27a by reducing lipid droplet accumulation in mature adipocytes. With respect to miRNA mimic replacement therapies, this approach might provide new therapeutic strategies to prevent or treat obesity and obesity-related disorders.
18 April 2019 in ACS Omega
Micro RNA (miRNA)-based medicines have attracted attention as new therapeutic strategies to treat genetic diseases and metabolic and immunological disorders. MiRNAs have emerged as key mediators of metabolic processes fulfilling regulatory functions in maintaining physiological conditions, while altered miRNA expression profiles are often associated with genetic diseases. However, naked miRNAs exhibit poor enzymatic stability, biomembrane permeation, and cellular uptake. To overcome these limitations, the development of appropriate drug delivery systems (DDS) is necessary. Herein, a DDS is characterized being assembled from miRNA-27a (negative regulator in fat metabolism) and the amphipathic N-TER peptide. Dynamic light scattering (DLS), electrophoretic light scattering, and atomic force microscopy (AFM) are used to investigate physicochemical properties (i.e., size, shape, and charge) of the DDS. Although surface charges should provide decent stabilization, the AFM results confirm a state of agglomeration, which is also suggested by DLS. Furthermore, AFM studies reveal adhesion on hydrophilic as well as hydrophobic substrates, which is related to the amphipathic properties of the N-TER peptide. Physicochemical properties of DDS are important parameters, which have an impact on cell internalization/uptake and have to be taken into account for in vitro studies to develop a successful peptide-based DDS for miRNA replacement therapy in metabolic diseases, such as obesity and others.
24 May 2022 in Journal of Pharmaceutical Innovation
Purpose: Inkjet printing has the potential to enable novel personalized and tailored drug therapies based on liposome and lipid nanoparticles. However, due to the significant shear force exerted on the jetted fluids, its suitability for shear-sensitive materials such as liposomes, has not been verified. We have conducted a proof-of-concept study to examine whether the particle concentration and size distribution of placebo liposomes are affected by common inkjet/dispensing technologies. Methods: We have subjected three types of liposome-containing fluids (“inks”) to two different commercial dispensing/jetting technologies, which are relevant to most drug printing approaches. The liposome jetting processes were observed in real-time using strobographic imaging techniques. The phospholipid concentrations and particle size distributions were determined before and after jetting via enzymatic colorimetric and dynamic light scattering methods, respectively. Results: Our results have shown that the jetting dynamics of the liposome inks are well predicted by the established inkjet printing regime map based on their physical properties and the jetting conditions. Importantly, although significant shear forces were confirmed during jetting, the liposome concentrations and particle size distributions in the collected samples remain largely unaffected. Conclusion: These findings, we believe, provide the essential proof-of-concept to encourage further development in this highly topical research area.